Tissue adhesive and chlorhexidine gluconate interaction: Implications for vascular access device securement

Amanda J Ullman1,2,3, Tim R Dargaville1,5 and Claire M Rickard1,2,3

Response to:

The growing evidence supporting tissue adhesive (TA), or medical-grade superglue, to promote vascular access security has resulted in rapid uptake in clinical settings.1,2 TA manufacturers are exploring different chemical compositions to optimize viscosity and strength while maintaining biocompatibility. However, TAs are being applied within already complex clinical situations. Many other chemicals are already being used, and interactions between current practices and emerging technologies need to be examined. We read with interest Di Puccio et al.’s1 laboratory study demonstrating the safety of applying TA onto a range of uncoated polyurethane peripherally inserted central catheters (PICCs), without adversely affecting the catheter surfaces or mechanical strength. This safety data are reassuring for clinicians currently applying TA onto PICCs made of these materials; however, the interaction with silicone demonstrates further testing with antimicrobial and anti-thrombogenic materials is important.

Further guidance regarding the application of TA is necessary, to ensure its success in the heterogeneous clinical settings where TA is being applied. Chlorhexidine gluconate (CHG) is a vital antiseptic used in combination with alcohol for skin decontamination.3 What is currently unknown from the literature and clinical practice is whether there is potential for adverse interaction between TA and CHG at vascular access insertion sites.

From a chemical perspective, CHG may interact with TAs in two ways. First, the mechanism in which cyanoacrylate TA polymerizes is based on trace amounts of water on skin or in the air initiating the chemical reaction. Both the chlorhexidine and gluconate components of CHG have the potential to act similarly to water and commence the cyanoacrylate TA reaction process. Thus, in the presence of CHG, TA’s hardening reaction may be accelerated which could, theoretically, change the adhesive strength. The second potential interaction is with the alcohol component of CHG (usually isopropanol), which if not fully allowed to evaporate before application of TA may possibly also affect the chemical reaction. Preliminary experiments on healthy volunteers showed 2-octyl cyanoacrylate (Dermabond™; Ethicon, USA) reacted faster and with greater heterogeneity on skin freshly swabbed with 2% CHG with 70% isopropyl alcohol (SoluPrep™ Swab; 3M, USA), compared with non-swabbed skin. The same TA applied to swabbed then dried skin reacted faster than the non-swabbed control, but only at the skin surface.

Dermatitis injuries caused by inadequate CHG drying time prior to dressing application are common.4 Vascular access device insertion and dressing change procedures can be harried, due to non-compliant patients (e.g. paediatrics) and staffing shortages. If TA becomes a primary securement method for vascular access devices, clinicians must ensure adequate CHG drying time, prior to TA application. Otherwise, this new innovation, instead of promoting device security, may possibly be associated with accidental dislodgement and consequential treatment disruption.

1Alliance for Vascular Access Teaching and Research Group, Menzies Health Institute Queensland, Griffith University, Nathan, QLD, Australia
2School of Nursing and Midwifery, Griffith University, Nathan, QLD, Australia
3Centre for Clinical Nursing, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia
4Paediatric Critical Care Research Group, Lady Cilento Children’s Hospital, Brisbane, QLD, Australia
5Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia

Corresponding author:
Amanda J Ullman, Alliance for Vascular Access Teaching and Research Group, Menzies Health Institute Queensland, Griffith University, N48, Nathan, QLD 4111, Australia.
Email: a.ullman@griffith.edu.au
Declaration of conflicting interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Griffith University has received investigator-initiated research grants from tissue adhesive and dressing manufacturers (3M, Adhezion, BD, Centurion Medical Products) to support the research of A.J.U., unrelated to the current manuscript. Griffith University has received investigator-initiated research/education grants on C.M.R.’s behalf from tissue adhesive and dressing manufacturers (3M, Adhezion, BBraun, BD-Bard, Centurion Medical Products, Entrotech, Medtronic, Teleflex), and consultancy payments from tissue adhesive and dressing manufacturers (3M, BBraun, BD-Bard, ResQDevices).

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

References